TABLE 2.

Evaluation of antibodies for immunoprecipitation of LVPs

AntibodyHost speciesAntigen% Antigen precipitateda% HCV RNA precipitatedb
Normal IgGRabbitNegative control011.4
Anti-ApoBRabbitHuman ApoB10091.8
Anti-ApoERabbitHuman ApoENTc95.0
Normal IgGGoatNegative control011.0
B65581GGoatHCV E23624.9
2G12-2MouseNegative control011.6
AP33MouseHCV E2278.5
3C7-C3MouseHCV E2 HVR-1NTc25.0
Normal IgGHumanNegative control07.7
CBH-5HumanHCV E25223.9
CBH-2HumanHCV E26719.1
CBH-7HumanHCV E21016.0
CBH-4DHumanHCV E207.7
  • a Calculated as the amount of antigen in the immunoprecipitate (percentage of antigen available in the sample prior to immunoprecipitation) (Fig. 5 and 6).

  • b Calculated as the titer of HCV RNA in the immunoprecipitate (percentage of total HCV RNA in the immunoprecipitate plus supernatant).

  • c NT, not tested.